For decades, cancer treatment followed a blunt logic: the organ where a tumor first appeared dictated the therapy. A lung cancer patient received lung cancer drugs, a breast cancer patient received breast cancer drugs, and if the first choice failed, the next was tried—often in a slow, discouraging cycle of trial and error.
That approach is now being upended by precision oncology, which treats cancer less like a disease of organs and more like a disease of genes. By sequencing the DNA of a patient’s tumor, doctors can identify the specific mutations driving its growth and select therapies that target those exact molecular vulnerabilities. The result, in many cases, is a treatment plan tailored to the biology of a single person’s cancer rather than the statistics of a population.
The shift is most visible in the expanding list of so-called targeted therapies and immunotherapies approved alongside companion diagnostic tests. These biomarkers—from EGFR and ALK mutations in lung cancer to HER2 amplification in breast cancer—have transformed certain once-grim diagnoses into manageable chronic conditions. Yet the revolution is incomplete. Many patients still lack access to comprehensive genomic testing, either because of cost, insurance gaps, or hospital infrastructure. And some oncologists caution that molecular findings are only part of the story: a tumor’s behavior also depends on its environment, the patient’s overall health, and how the cancer evolves under pressure from treatment.
None of this means precision medicine is a cure-all, nor that older methods will disappear overnight. But it does mean the field is finally moving toward a more honest model of cancer—one that acknowledges that two patients with the same diagnosis can have profoundly different diseases, and that the best treatment starts with understanding those differences rather than guessing at them.